Vincerx Pharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 42
- Market Cap
- $23.7M
- Website
- http://vincerx.com
- Introduction
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Vincerx Pharma, Inc. announced a proposed merger with Oqory, Inc., aiming to enhance its pipeline with Oqory's Phase 3 TROP2 ADC. Post-merger, Oqory equity holders will own ~95% of the combined entity. The deal includes a $13.66M equity value for Vincerx stockholders and a $20M equity offering. Oqory's ADC, OQY-3258, shows promising efficacy and safety in clinical trials.
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma
DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.
2024 PharmaVoice 100s: Cancer Care Visionaries
Cancer has become more manageable due to tailored treatments, with leaders in oncology pushing for genetic insights and data research. This year's Cancer Care Visionaries include Dr. Hesham Abdullah, Jason Bock, Arnon Chait, Raffaele Colombo, Dr. Yusri Elsayed, Mark Erlander, Dr. Marjorie Green, Raquel Izumi, Dr. Biljana Naumovic, Dr. Amita Patnaik, Dr. Mary Pinder-Schenck, Amoolya Singh, and AmirAli Talasaz, each contributing unique perspectives on cancer therapy and leadership.
© Copyright 2025. All Rights Reserved by MedPath